Anti-platelet membrane glycoprotein vi monoclonal antibody
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsHIROSHI TAKAYAMA, KAMON SHIRAKAWA, SHOJI FURUSAKO, YOSHITAKA HOSAKA, TOMOKAZU MATSUSUE, KATSUKI NAITOH, YUMI HOTTA, TETSUSHI KAWAHARA, MOTOYASU HONDA
Life of this patent
Estimating the term…
Abstract
The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
Claims30
An isolated antibody or antigen-binding fragment thereof that specifically binds to a human platelet glycoprotein VI (GPVI) protein comprising an H-chain having the amino acid sequences in VH CDR1, VH CDR2, and VH CDR3, respectively, of:
- (i) SEQ ID NOs:
- 15, 16, and 17;
- (ii) SEQ ID NOs:
- 18, 19, and 20;
- (iii) SEQ ID NOs:
- 24, 25, and 26;
- (iv) SEQ ID NOs:
- 27, 28, and 29;
- (v) SEQ ID NOs:
- 42, 43, and 44;
- (vi) SEQ ID NOs:
- 48, 49, and 50;
- (vii) SEQ ID NOs:
- 335, 336, and 337;
- (viii) SEQ ID NOs:
- 338, 339, and 340;
- (ix) SEQ ID NOs:
- 341, 342, and 343;
- (x) SEQ ID NOs:
- 344, 345, and 346;
- (xi) SEQ ID NOs:
- 347, 348, and 349;
- (xii) SEQ ID NOs:
- 350, 351, and 352;
- (xiii) SEQ ID NOs:
- 353, 354, and 355;
- (xiv) SEQ ID NOs:
- 356, 357 and 358;
- (xv) SEQ ID NOs:
- 359, 360, and 361;
- (xvi) SEQ ID NOs:
- 362, 363, and 364;
- (xvii) SEQ ID NOs:
- 365, 366, and 367;
- (xviii) SEQ ID NOs:
- 368, 369, and 370;
- (xix) SEQ ID NOs:
- 371, 372, and 373;
- or
- (xx) SEQ ID NOs:
- 374, 375, and 376.
An isolated antibody or antigen-binding fragment thereof that specifically binds to a human platelet glycoprotein VI (GPVI) protein comprising an L-chain having the amino acid sequences in VL CDR1, VL CDR2 and VL CDR3, respectively, of:
- (i) SEQ ID NOs:
- 54, 55 and 56;
- (ii) SEQ ID NOs:
- 60, 61 and 62;
- (iii) SEQ ID NOs:
- 63, 64 and 65;
- (iv) SEQ ID NOs:
- 78, 79, and 80;
- (v) SEQ ID NOs:
- 84, 85 and 86;
- (vi) SEQ ID NOs:
- 377, 378, and 379;
- (vii) SEQ ID NOs:
- 380, 381, and 382;
- (viii) SEQ ID NOs:
- 383, 384, and 385;
- (ix) SEQ ID NOs:
- 386, 387, and 388;
- (x) SEQ ID NOs:
- 389, 390, and 391;
- (xi) SEQ ID NOs:
- 392, 393, and 394;
- (xii) SEQ ID NOs:
- 395, 396, and 397;
- (xiii) SEQ ID NOs:
- 398, 399 and 400;
- (xiv) SEQ ID NOs:
- 401, 402, and 403;
- (xv) SEQ ID NOs:
- 404, 405, and 406;
- (xvi) SEQ ID NOs:
- 407, 408, and 409;
- (xvii) SEQ ID NOs:
- 410, 411, and 412;
- (xviii) SEQ ID NOs:
- 413, 414, and 415;
- or
- (xix) SEQ ID NOs:
- 416, 417, and 418.
Dependencies are inferred from the claim text.